About this course
GLP-1s and Eating Disorders: Exploring Therapeutic Potential and Clinical Caution in Binge Eating Treatment Pathways GLP-1 receptor agonists, originally developed for type 2 diabetes and now widely used for weight management, are increasingly being considered for off-label use in individuals with binge eating disorder (BED) and related conditions. As these medications impact satiety, appetite regulation, and reward-related eating, some clinicians and clients are exploring whether they may offer therapeutic benefit, particularly in treatment-resistant cases. However, their use in populations with eating disorders is highly controversial and potentially harmful. This presentation critically examines the emerging evidence surrounding GLP-1s and their application in the treatment of BED and other eating disorders. It will explore whether, how, and when GLP-1s might be useful within the treatment pathway, while also addressing the significant clinical, ethical, and systemic risks associated with their use. Attendees will be introduced to current research on GLP-1s and appetite regulation, including their potential to reduce binge episodes by decreasing impulsivity and enhancing satiety. However, the session will also highlight the limitations of this research, including the frequent exclusion of individuals with active or historical eating disorders from clinical trials, short follow-up periods, and a focus on weight outcomes rather than psychological recovery. Importantly, the presentation will address a range of potential harms. These include the risk of reinforcing weight-centric thinking in vulnerable individuals, triggering restrictive behaviours or eating disorder symptom migration, and masking underlying trauma or emotional distress that drives disordered eating. The medicalisation of distress and the overemphasis on pharmacological control may also undermine client autonomy and recovery goals. The session will consider specific scenarios where GLP-1s have been introduced-both appropriately and inappropriately-including case examples highlighting complex outcomes. It will also explore how these medications may impact therapeutic engagement, body image, and identity in recovery. Clinicians will be invited to critically reflect on their own assumptions around weight, health, and 'success' in treatment. Practical guidance will be offered for assessing when GLP-1s may pose more harm than benefit, how to support informed consent, and how to navigate conversations with clients who may be exploring or requesting these medications, particularly in the context of widespread media exposure. Ultimately, this session aims to foster thoughtful, balanced, and ethically sound dialogue around the integration of emerging pharmacological tools into the care of individuals with BED and other eating disorders. Rather than providing a simple endorsement or rejection, it will emphasise the importance of timing, clinical judgement, client readiness, and multidisciplinary oversight. Participants will leave with a nuanced understanding of the role GLP-1s may or may not play in eating disorder treatment, and greater confidence in evaluating the clinical, psychological, and ethical dimensions of their use.
